Cochrane Abstracts
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Pembrolizumab Monotherapy Versus Chemotherapy for Treatment of Advanced Urothelial Carcinoma With Disease Progression During or Following Platinum‐containing Chemotherapy. a Cochrane Rapid Review." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439432/all/Pembrolizumab_monotherapy_versus_chemotherapy_for_treatment_of_advanced_urothelial_carcinoma_with_disease_progression_during_or_following_platinum‐containing_chemotherapy__A_Cochrane_Rapid_Review.
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439432/all/Pembrolizumab_monotherapy_versus_chemotherapy_for_treatment_of_advanced_urothelial_carcinoma_with_disease_progression_during_or_following_platinum‐containing_chemotherapy__A_Cochrane_Rapid_Review. Accessed March 17, 2025.
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439432/all/Pembrolizumab_monotherapy_versus_chemotherapy_for_treatment_of_advanced_urothelial_carcinoma_with_disease_progression_during_or_following_platinum‐containing_chemotherapy__A_Cochrane_Rapid_Review
Pembrolizumab Monotherapy Versus Chemotherapy for Treatment of Advanced Urothelial Carcinoma With Disease Progression During or Following Platinum‐containing Chemotherapy. a Cochrane Rapid Review [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439432/all/Pembrolizumab_monotherapy_versus_chemotherapy_for_treatment_of_advanced_urothelial_carcinoma_with_disease_progression_during_or_following_platinum‐containing_chemotherapy__A_Cochrane_Rapid_Review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
ID - 439432
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439432/all/Pembrolizumab_monotherapy_versus_chemotherapy_for_treatment_of_advanced_urothelial_carcinoma_with_disease_progression_during_or_following_platinum‐containing_chemotherapy__A_Cochrane_Rapid_Review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
